PIV5 as an oncolytic agent
AssigneeUniversity of Georgia Research Foundation, Inc.
InventorBiao He
Life of this patent
Estimating the term…
Abstract
The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5VΔC), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI−), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI−, rPIV5-CPI+, rPIV5-Rev, rPIV5-RL, rPIV5-P-S157A, rPIV5-P-S308A, rPIV5-L-A1981D, rPIV5-F-5443P, rPIV5-MDA7, rPIV5ΔSH-CPI−, or rPIV5ΔSH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents.
Claims17
A method of inducing tumor cell syncytia formation in a subject with a tumor, the method comprising administering to the subject a composition comprising an isolated parainfluenza virus 5 (PIV5) mutant in an amount effective to induce tumor cell syncytia, wherein the PIV5 mutant comprises a mutation lacking the C-terminus of the V protein (rPIV5VAC) and further comprises a heterologous nucleotide sequence encoding a tumor killing heterologous polypeptide and/or heterologous RNA.
Dependencies are inferred from the claim text.